Share this article Share this article HistoIndex joins forces with a consortium of partners from NHS Health Boards, UK universities and technology companies for the development of a novel AI-based integrated diagnostic tool. There is currently no available method to accurately identify patients with NAFLD who are at a higher risk of developing a more progressive form of liver disease (non-alcoholic steatohepatitis or NASH) that can lead to cirrhosis, liver cancer and premature death. NASH is an unmet liver condition that awaits an FDA-approved treatment. Having an AI-based diagnostics tool that provides a fully quantitative and accurate assessment of fibrosis will provide clinicians with a deeper understanding of the disease and its progressive features, which will aid in enrolling high-risk patients for NASH clinical trials.